A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation

Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor. This case highlights the unique nature of spiradenocarcinomas as well as the potential benefit of targeted thera...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology (Williston Park, N.Y.) N.Y.), 2024-06, Vol.38 (6), p.230-231
Hauptverfasser:	Trinh, Jonathan Q, Banskota, Shristi Upadhyay, Marr, Alissa S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Biopsy Cancer therapies Cell cycle Chemotherapy Cyclin-Dependent Kinase 4 - genetics Cyclin-Dependent Kinase 6 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - genetics Cyclin-Dependent Kinase Inhibitor p16 - genetics Dissection Female Genetic aspects Humans Literature reviews Lymphatic system Male Medical imaging Metastasis Middle Aged Mutation Pathology Pemetrexed Piperazines - therapeutic use Protein Kinase Inhibitors - therapeutic use Pulmonary arteries Pyridines - therapeutic use Radiation Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - pathology Sweat Gland Neoplasms - drug therapy Sweat Gland Neoplasms - genetics Sweat Gland Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor. This case highlights the unique nature of spiradenocarcinomas as well as the potential benefit of targeted therapy.
ISSN:	0890-9091
DOI:	10.46883/2024.25921022